Start: February 2016
End: February 1, 2024
Primary progressive aphasia (PPA) is a type of dementia that involves changes in the ability to use language to speak, read, write, and understand what others are saying. New tools are needed to help diagnose PPA. This study will test the effectiveness of the radioactive tracer, 18F-AV-1451, to detect the amount and location of tau, a protein that accumulates abnormally in the brains of people diagnosed with PPA. All participants will receive an injection of the tracer and then a positron emission tomography (PET) scan. The researchers will review the brain scans for the identification of tau patterns and monitor participants for any side effects.
Minimum Age: 20 Years
Maximum Age: 100 Years
Contact study personnel listed either under the general study contact or the location nearest you.
Cognitive Neurology and Alzheimer's Disease Center - Northwestern University
Chicago, IL 60611
Lead: Northwestern University
Source: ClinicalTrials.gov ID: NCT03283449